TrianglecDC1 Vaccine (NCT07694986)
cDC1 Vaccine trial for Breast Cancer (NCT07694986). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with breast cancer involving the brain or spinal-fluid linings, confirmed by fluid testing or imaging. Prior brain radiation and an Ommaya-type reservoir are required.
The idea: patients receive vaccines made from their own dendritic cells, loaded with HER proteins, directly into spinal fluid. HER2-positive patients also receive HER2-targeting trastuzumab weekly; HER2-negative patients receive PD1-blocking nivolumab every two weeks. Researchers first establish a tolerated vaccine dose, then assess survival and safety.
This phase 2 study plans 30 patients. Peter Forsyth leads at Moffitt, Tampa, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.